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Abstract
The RENAAL Study is a double-blind, placebo-
controlled trial to evaluate the renal protective effects of
losartan in Type 2 diabetic patients with nephropathy.
The study has enrolled 1513 patients and is expected to
continue for 3.5 years after the last patient has been
entered. Eligible patients must have a urinary
albumin:creatinine ratio of at least 300 mg/g and serum
creatinine between 1.3 to 3.0 mg/dL. Eligible 
hypertensive or normotensive patients are randomised to
receive either losartan or placebo, in addition to their
existing antihypertensive therapy. Medications that block
angiotensin production or action, are excluded. The 
primary endpoint is a composite of the time to first
event of doubling of serum creatinine, end-stage renal
disease, or death; secondary endpoints include 
cardiovascular events, progression of renal disease, and
changes in proteinuria; tertiary endpoints include quality
of life, healthcare resource utilisation, and amputations.
Patients include Caucasians (48.6%), Blacks (15.2%),
Asians (16.7%), and Hispanics (18.2%). Baseline
urinary albumin:creatinine ratio and serum creatinine
levels average 1867 mg/g and 1.9 mg/dL, respectively.
Mean systolic and diastolic blood pressures are 153 and
82 mmHg, respectively. RENAAL will document
whether blockade of the AII receptor with losartan
produces clinical benefits in patients with Type 2
diabetes and nephropathy.
Introduction
End-stage renal disease (ESRD) continues to repre-
sent a worldwide public health concern. The inci-
dence of newly-treated cases of ESRD has risen over
the last decade in the United States.1 Recent esti-
mates by the National Institute of Diabetes and
Digestive and Kidney Diseases indicate that diabetes
mellitus represents the single largest cause of ESRD
requiring chronic dialysis or kidney transplantation
and accounts for approximately 42% of new cases of
ESRD in the U.S. in 1997.1 The incidence of ESRD in
patients with Type 2 diabetes has risen sharply in
recent years in many regions of the world, including
the United States.1-8
The prognosis of diabetic patients with ESRD is
bleak – 30% of diabetic patients undergoing dialysis
and 15% of diabetic patients receiving their first
cadaveric kidney transplants die within two years.9,10
Preventing or delaying the progression of diabetic
nephropathy to ESRD by dietary modification,
medical therapy, and/or other means of lifestyle
modification, is therefore an essential manage-
ment goal.
Studies in experimental models of diabetic and
nondiabetic renal disease show that losartan,a selec-
tive angiotensin II (Ang II) receptor antagonist
(AIIA) reduces proteinuria and ameliorates patho-
logical changes associated with the progression of
renal disease.11-15 Losartan has also been demonstrat-
ed to reduce proteinuria in diabetic and nondiabet-
ic patients with renal disease, as well as in patients
with renal transplant.16-19
Although these studies have shown a beneficial
effect on proteinuria in patients with Type 2 dia-
betes,the RENAAL study is being performed in order
to prove that blockade of the Ang II AT1-receptor
may have a beneficial effect on the progression of
renal disease by retarding deterioration of renal
function and decreasing cardiovascular and overall
mortality.
To further investigate the long-term renal pro-
tective effects of losartan,the RENAAL (Reduction of
Endpoints in NIDDM with the Angiotensin II
Antagonist Losartan) Study was initiated in patients
with Type 2 diabetes and nephropathy. The RENAAL
study will investigate whether losartan, either alone
or in combination with conventional antihyperten-
sive therapy,will reduce the number of patients with
Type 2 diabetes experiencing a doubling of serum
creatinine, ESRD, or death compared with placebo-
treated patients (with or without conventional anti-
hypertensive therapy). In addition, the study will
assess the effects of losartan vs. placebo on cardio-
vascular morbidity, mortality, progression of renal
disease (slope of the reciprocal of serum creatinine),
and proteinuria, as well as the impact of losartan
therapy on quality of life and healthcare resource
utilisation.
Methods
This multinational, double-blind, randomised, place-
bo-controlled study is evaluating the renal protective
effects of losartan in a total of 1513 patients with
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Type 2 diabetes and nephropathy. The study was ini-
tiated in 1996, and patient enrollment was complet-
ed in 1998. All patients will be followed for 3.5 years
after the last patient has been randomised.To be eli-
gible for enrollment in the study, male or female
patients ranging in age from 31 to 70 years diag-
nosed with Type 2 diabetes must have had two qual-
ifying urinary albumin:creatinine ratios on first
morning specimen of at least 300 mg/g (or a 24-hour
urine protein of greater than 500 mg) and two qual-
ifying serum creatinines between 1.5 to 3.0 mg/dL
(1.3 mg/dL for females) (Table 1). Eligible patients
with Type 2 diabetes could have been either hyper-
tensive or normotensive. Type 2 diabetes was
defined as those patients who were diagnosed after
the age of 30, who did not require insulin within six
months of diagnosis, and who had no history of dia-
betic ketoacidosis. However, if one of these criteria
for Type 2 diabetes was not met, a C-peptide level
must have been within normal range to confirm the
diagnosis. Patients were excluded from the study if
they had been diagnosed with Type 1 diabetes or
nondiabetic renal disease, including renal artery
stenosis. Patients with a history of heart failure,
myocardial infarction, coronary artery bypass graft-
ing,cerebral vascular accident,percutaneous translu-
minal coronary angioplasty, or transient ischaemic
attacks within 1–12 months prior to study enroll-
ment were excluded. Serum potassium levels  <3.5
or >5.5 mEq/L, and chronic use of NSAIDs and
aspirin >325 mg/day, also precluded patients from
entering the study.
Statistical evaluation
The sample size calculation for this trial was based
upon the assumption that the five-year rate of the
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Table 1 Principal inclusion and exclusion criteria for the RENAAL study.
Inclusion criteria
● Type 2 diabetes defined as:
- >30 years of age at diagnosis (younger patients admitted on individual basis if C-peptide levels confirm Type 2 diabetes)
- Insulin not required within six months of initial diagnosis
- No history of diabetic ketoacidosis
- Currently treated with diet, oral hypoglycaemics, or insulin
● Proteinuria (urinary albumin:creatinine ratio  ≥300 mg/g) or 24-hour urine protein >500 mg
● Serum creatinine ≥1.5 to 3.0 mg/dL (≥1.3 mg/dL for females)
● Hypertensive (sitting BP ≤200/110 mmHg) or normotensive (sitting systolic BP ≥100 mmHg) 
● Glycosylated haemoglobin (A1c) <12%
● Aged 31 to 70 years  
● Female patients of childbearing potential required to have a negative pregnancy test and use an approved birth control method 
● All patients to give written informed consent before enrollment
Exclusion criteria
● Type 1 diabetes
● History of nondiabetic renal disease
● History of MI, CABG within past one month; CVA, PTCA within past six months; or TIA within the past 12 months
● History of heart failure 
● Renal artery stenosis, primary aldosteronism, or phaeochromocytoma
MI = myocardial infarction, CABG = coronary artery bypass grafting, CVA = cerebral vascular accident, PTCA = percutaneous 
transluminal coronary angioplasty, TIA = transient ischemic attacks, BP = blood pressure
Figure 1  Overview of the design of the RENAAL study.
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first time to event of the composite endpoints of
doubling of serum creatinine/ESRD/death in the
placebo group would be 58% and that this rate
would be reduced by 20% in the losartan group. In
order to have 95% power at the 4.8% significance
level (two-sided, adjusted for interim analyses), the
trial required the enrollment of at least 1320
patients and follow-up of the last enrolled patient
for 3.5 years.
In general, all primary efficacy analyses will be
based on the intention-to-treat principle. All
patients will be analysed according to the treat-
ment to which they were randomly assigned.
A formal interim analysis is planned for effica-
cy when the last patient has been followed for
two years or when half of the expected primary
endpoints have occurred, whichever comes first.
The interim analysis will be performed in accor-
dance with recommendations from an indepen-
dent Data and Safety Monitoring Board (DSMB).As a
result of this interim analysis, the final α-level for
declaring a significant difference between treatment
groups must be 0.048. In addition to reviewing the
formal interim analysis, the DSMB is charged with
identifying safety issues and interpreting emerging
safety study data in order to make periodic recom-
mendations on study continuation, termination or
protocol modification.
An independent, blinded endpoint committee
is adjudicating all potential clinical endpoints
occurring from the time of randomisation until
study termination, in order to determine whether
an event is a true endpoint (as per the guidelines
established in the RENAAL Endpoint Adjudication
Manual).
Study design
The RENAAL study began with an initial screen-
ing-treatment phase lasting six weeks (Figure 1).
During this phase, in which placebo was not
administered, hypertensive patients being treated
with either an angiotensin-converting enzyme
inhibitor (ACE-I) or AIIA within six weeks of trial
enrollment discontinued these medications and
received an alternative standard antihypertensive,
(open-label diuretic, beta blocker, calcium-channel
blocker [CCB],or alpha blocker) as appropriate, to
control their hypertension. Hypertensive patients
not being treated with an ACE-I or AIIA continued
to receive their existing standard antihypertensive
therapy. Patients with normal blood pressure did
not receive any antihypertensive treatment during
this phase. During the screening-treatment phase,
patients underwent a medical history, physical
examination, and electrocardiography. Electrocar-
diograms (ECGs) are performed in this study, not
only as part of standard medical practice, but as a
means to identify silent myocardial infarctions
(MI), which are considered a secondary efficacy
endpoint. A central ECG lab interprets all ECGs
conducted throughout the study, exclusively for
the detection of silent MI. Throughout the screen-
ing phase, patients also provide a random urine
sample for urinalysis with microscopy, urine sam-
ples (first morning void) for determination of uri-
nary albumin/creatinine ratio and blood samples
for serum chemistry and haematology parameters.
With the exception of the urinalysis with
microscopy, all urine and blood assessments are
performed at a central laboratory. Trough blood
pressure measurements are obtained at every visit.
The screening-treatment phase has been fol-
lowed by a double-blind treatment phase which will
last 3.5 years after the last patient has been ran-
domised. The double-blind phase began with the
randomisation of eligible patients to either losartan
(50 mg daily) or placebo groups (Day 1). Patients
were randomised according to a computer-generat-
ed random allocation schedule. The randomisation
was stratified based on the level of baseline albu-
minuria. Patients will continue to receive study ther-
apy (losartan or placebo), in addition to their exist-
ing antihypertensive therapy, for the duration of the
study.On the morning of the clinic visit, the patients
are instructed not to take their antihypertensive
medications, including the study drug, until trough
blood pressure has been measured. If the target
trough blood pressure of less than 140/90 mmHg is
not achieved after the first four weeks of therapy or
at any phase during the study, the dose of losartan
(or placebo) is increased to two pills (i.e., 100 mg)
daily,however, if the 100 mg losartan dose is not suf-
ficient to reduce trough blood pressure below target
values, additional open-label antihypertensives are
added. Open-label antihypertensives include
diuretics, beta-blockers, calcium channel blockers,
alpha blockers or centrally-acting agents. In addi-
tion, to assist in this aspect of the study, the
Steering Committee has provided blood pressure
treatment guidelines to investigators.Throughout
the trial, patients continue to receive standard
medical care for treatment of diabetes, including,
but not limited to, blood pressure monitoring, rou-
tine measurements of HbA1c and fasting blood
glucose concentrations. Patients from both losar-
tan and placebo groups will not be permitted to
receive ACE-I or other AIIAs throughout the study.
Efficacy assessments
Patients return to the clinic for assessment at one
week, one month and three months, and are con-
tinuing to return at intervals of three months over
the 3.5-year study duration. Several key measure-
ments are made at these time-points, including
trough sitting blood pressure and heart rate, labo-
ratory measurements (urinary albumin/creatinine
ratio,blood chemistry, and haematology),healthcare
resource utilisation, and yearly urinalyses, physical
examinations and ECGs. In addition, quality of life
questionnaires are completed by patients at each
visit in the U.S. only. A subgroup of the total patient
population will be analysed with regard to 24–hour
urine collections at three-month intervals for total
protein excretion and creatinine clearance determi-
nations.
The primary efficacy parameter of the RENAAL
study is a composite endpoint composed of the
time to first event of doubling serum creatinine,
ESRD,or death.ESRD has been defined as the need
for chronic dialysis or renal transplantation.
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Secondary efficacy endpoints include the assess-
ment of cardiovascular events (e.g. MI, stroke,
death from coronary heart disease, other cardio-
vascular-related death, coronary or peripheral
revascularisation procedures, and hospitalisation
for unstable angina, or heart failure), progression
of renal disease (slope of the reciprocal of serum
creatinine),20 and changes in proteinuria, as mea-
sured by the urine albumin to creatinine ratio.
Tertiary efficacy endpoints include health-related
quality of life (U.S. patients only), healthcare
resource utilisation, and incidence of amputation.
Quality of life is being assessed using the SF-36
generic health profile instrument. The SF-36 is
composed of numerous domains of health-related
quality of life, including, but not limited to, physi-
cal function, bodily pain, general health, social
function and mental health. The EQ-5D quality-
adjusted life year instrument is being used to
determine whether increasing the time to first
event of doubling of serum creatinine, ESRD, or
death leads to greater quality–adjusted life expectan-
cy in patients treated with losartan compared with
those on placebo.21,22 Healthcare resource utilisation
data (based on ICD-9-CM codes) will be calculated
only for costly episodes of care (e.g. hospitalisations
and medical procedures). Throughout the trial, the
safety and tolerability of losartan is being assessed.
Baseline characteristics
One thousand, five hundred, and thirteen (1513)
patients have been enrolled in the RENAAL study.
Approximately 50% of these patients were taking
either an ACE-I or AIIA upon entering the screen-
ing treatment phase of the study. The greatest
number of patients were enrolled in North
America (45.5%), followed by approximately equal
numbers in Asia, Europe and Latin America (Table
2).The patient population is comprised of 48.6%
Caucasian, 15.2% Black, 16.7% Asian, 18.2%
Hispanic, and 0.2% Native American (Table 3).
Enrolled patients (63.2% male, 36.8% female) have
a mean (SD) age of 59.6 (7.4) years. Urinary albu-
min:creatinine ratio and serum creatinine levels
averaged (SD) 1867 (2699) mg/g and 1.9 (0.5)
mg/dL, respectively, and mean (SD) glycosylated
haemoglobin (HbA1c) was 8.5 (1.6) %. Mean (SD)
body mass index was 29.7 (6.3) kg/m2. Mean (SD)
systolic and diastolic blood pressures at baseline
were 153 (19) and 82 (10) mmHg (MAP=106
mmHg), respectively. Retinopathy (62%), lipid dis-
orders (53.7%), neuropathy (49.2%), and cataracts
(25.0%), represented the most common concur-
rent conditions observed at baseline (Table 4).
Discussion
The key factors that prompted initiation of this
long-term study of losartan in patients with Type 2
diabetes and nephropathy were the high preva-
lence of  Type 2 diabetes throughout the world,
the high incidence of ESRD in diabetic patients,
and the lack of conclusive data on the effect of
blockade of the renin-angiotensin-aldosterone sys-
tem (RAAS) on the progression of renal disease and
mortality in Type 2 diabetics with nephropathy.
Worldwide,an estimated 146 million people have
Type 2 diabetes.23 By 2010,the prevalence is expect-
ed to increase approximately 1.5-fold to a projected
210 million people around the world.23 The rate of
growth of Type 2 diabetes, which is reaching epi-
demic proportions in many countries throughout
the world,can be attributed to a longer life span,obe-
sity,diet and reduced exercise,among other factors.23 
Table 2 Enrollment of patients in RENAAL according 
to region.
Region %
Asia 17.0
(Hong Kong, Israel, Japan, Malaysia, Singapore)
Europe 19.3
(Austria, Czech Republic, Denmark, France, 
Germany, Hungary, Italy, Netherlands, 
Portugal, Russian Federation, Slovakia, Spain, 
United Kingdom)
Latin America 18.1
(Argentina, Brazil, Chile, Costa Rica, Mexico, 
Peru, Venezuela)
New Zealand 0.2
North America 45.5
(Canada, United States of America)
Table 3 Baseline characteristics of patients enrolled 
in RENAAL.
Baseline N % Mean SD 
characteristic
Race 1512* 100.0
Caucasian 735 48.6
Black 230 15.2
Asian 252 16.7
Hispanic 275 18.2
Native American 3 0.2
Other 17 1.1
Sex 1512 100.0
Female 556 36.8
Male 956 63.2
Age 1512 100.0 59.6 7.4
< 60 670 44.3 52.8 5.3
61-70 797 52.7 64.7 3.0
71-75 45 3.0 71.6 0.7
Body Mass 
Index (kg/m2) 1472 29.7 6.3
Blood pressure 1512
Systolic (mmHg) 1511 153 19
Diastolic (mmHg) 1511 82 10
Laboratory 
values 1510
Urinary alb:creat (mg/g) 1509 1867 2699
Serum creat (mg/dL) 1510 1.9 0.5
HbA1c (% of total Hb) 1494 8.5 1.6
Serum cholesterol (mg/dL) 1494 228.0 55.5
ALT (u/L) 1494 18.0 11.4
AST (u/L) 1494 18.2 9.0
Serum bilirubin (mg/dL) 1494 0.6 0.2
Serum Potassium (mEq/l) 1510 4.6 0.5
Serum Uric Acid (mg/dl) 1510 6.7 1.7
* Data from one patient was not incorporated into the database at
the time of table generation. Alb:creat = albumin:creatinine ratio, 
creat =  creatinine, Hb = haemoglobin, HbA1c = glycosylated 
haemoglobin A1c, ALT = alanine transaminase, AST = aspartate 
transaminase
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A number of different treatment modalities
have been evaluated to delay the progression of
diabetic nephropathy, including modified protein
intake,24,25 strict glycaemic control,26-28 and antihy-
pertensive therapy.29-31 The importance of tight
blood pressure control in reducing the risk of
macrovascular and microvascular complications
in Type 2 diabetes is illustrated by the recent find-
ings of the United Kingdom Prospective Diabetes
Study (UKPDS) and the HOT study.31,32 The UKPDS
is a multicentre, randomised, controlled study that
showed that tight blood pressure control (mean
blood pressure, 144/82 mmHg) achieved a clini-
cally important reduction in the risk of death and
complications related to diabetes (e.g., non-fatal
MI, angina, heart failure, renal failure, and amputa-
tions) and progression of diabetic retinopathy.The
HOT study also provides evidence that strict
blood pressure control plays an important role in
reducing cardiovascular complications of dia-
betes.32 In this study, a 51% reduction in major car-
diovascular events (including MI, stroke, and car-
diovascular mortality) was observed in patients
with diabetes whose diastolic blood pressure was
less than, or equal to 80 mmHg. In addition,
Parving and colleagues demonstrated that antihy-
pertensive therapy produced a reduction in
blood pressure and albuminuria, as well as an
attenuation in the decline of glomerular filtration
rate (GFR) in patients with Type 1 diabetes.29 A
reduction in systemic blood pressure and the asso-
ciated fall in intraglomerular pressure may be an
important mechanism by which antihypertensive
agents attenuate the progression of diabetic
nephropathy.
In the RENAAL patient population,baseline mean
blood pressure (namely systolic blood pressure) indi-
cates suboptimal control prior to enrollment in the
study. Based on the published literature, discussed
previously, and the current recommendations for
controlling blood pressure in patients with diabetes,
it is imperative that we aim for aggressive reductions
in blood pressure in this patient population.
Furthermore, it is essential that blood pressure con-
trol in both treatment groups remain comparable.
Assessment of the primary efficacy parameters
would be difficult, if not impossible, with unequal
blood pressure control between treatment groups.
Optimal blood pressure control with different
classes of antihypertensive agents have shown that
the progression of diabetic nephropathy can be
delayed,and the risk of cardiovascular morbidity and
mortality can be reduced. It has been suggested,
however, that antihypertensive drugs that block the
RAAS may be more effective in delaying the pro-
gression of diabetic nephropathy than conventional
antihypertensive therapies. Ang II plays an impor-
tant role in the progression of renal injury through
haemodynamic and nonhaemodynamic mecha-
nisms; therefore, it is believed that blockade of the
Ang II receptor would offer renal protection beyond
reduction in systemic blood pressure. Studies in
patients with Type 1 diabetes have shown that ACE-I
effectively diminish the progression of nephropathy
above and beyond their blood pressure-lowering
effects.33 Also, in Type 1 diabetics with overt
nephropathy, captopril therapy produced a 50%
reduction in the risk of doubling of serum creati-
nine and the combined endpoints of ESRD and
death compared with patients treated with place-
bo.34 These findings suggest that blockade of the
RAAS may offer renal protection in patients with
Type 1 diabetes. Limited data exists on the effects
of blockade of the RAAS on the progression of dia-
betic nephropathy in Type 2 diabetes. Although
there are some similarities in the natural history of
nephropathy between Type 1 and Type 2 diabetes,
patients with Type 2 diabetes are typically older,
with long-standing hypertension, advanced ather-
osclerotic changes, insulin resistance, and a high
incidence of morbidity and mortality from cardio-
vascular disease.
At least two studies have been conducted in nor-
motensive, Type 2 diabetic patients which demon-
strated a long-term stabilising effect of ACE-I on plas-
ma creatinine and proteinuria.35,36 However, this
effect was not associated with differences in
glomerular filtration rate between treatment groups
over the same time course.36 Nevertheless, there are
no studies with ACE-I demonstrating the beneficial
effects of this class of drugs on ESRD and mortality
in patients with Type 2 diabetes and kidney disease.
In fact, data from the UKPDS did not show any dif-
ference between the effects of ACE inhibition and β-
blockade on renal and cardiovascular endpoints.37
The AIIAs, such as losartan, represent the newest
class of drugs to treat hypertension, and they appear
to offer many of the therapeutic benefits of ACE-I
with a more favourable side-effect profile.38-41
Losartan is an orally active,highly specific antagonist
Table 4 Baseline, concurrent conditions of patients 
enrolled in RENAAL.
Category N %
Cardiovascular system 715 47.4
Angina pectoris 142 9.4
Myocardial infarction 165 10.9
History of coronary revascularisation 138 9.1
Stroke 152 10.1
Transient ischaemic attack 29 1.9
Carotid disorders 54 3.6
Hemic lymphatic
Anaemia 308 20.4
Metabolic disorders
Lipid disorders 810 53.7
Musculoskeletal
Amputation 107 7.1
Nervous system
Neuropathy 743 49.2
Ophthalmic system 1113 73.8
Blindness 54 3.6
Cataracts 377 25.0
Glaucoma 104 6.9
Laser therapy and photocoagulation 138 9.1
Other ophthalmic disorders 161 10.7
Retinopathy 935 62.0
Urogenital
Impotence and sexual dysfunction 169 11.2
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that blocks the binding of Ang II to the AT1-receptor
subtype.Losartan has been shown to be well-tolerat-
ed in patients with varying degrees of renal dysfunc-
tion, including those on haemodialysis and those
who have undergone renal transplantation.19,42-44
In patients with renal disease, both with and
without diabetes, it has been demonstrated that
losartan reduces proteinuria to a similar extent to
ACE-I. In a pilot study and subsequent follow-up
study performed in hypertensive patients with
renal disease, Gansevoort and colleagues found
that losartan treatment (50 or 100 mg daily) low-
ered blood pressure, decreased urinary protein
excretion, and elevated renal plasma flow to a
degree comparable to that found with ACE-I.16,17
The anti-proteinuric effect of losartan has also
been demonstrated in a double-blind, cross-over
study comparing losartan with amlodipine in
hypertensive patients with nondiabetic nephropa-
thy.18 In this study, both losartan and amlodipine
significantly lowered blood pressure, but only
losartan significantly reduced proteinuria after
four weeks of treatment.18 In patients with Type 2
diabetes, losartan has been shown to reduce
proteinuria45 and to reduce proteinuria similar to
ACE-I.46
In recent years,the results of large,long-term clin-
ical trials have been published, comparing the
effects of ACE inhibition with those of conventional
treatment on cardiovascular morbidity and mortali-
ty.47-50 The most recently published Heart Outcomes
Prevention Evaluation (HOPE) study demonstrated
that the risk of cardiovascular morbidity and mortal-
ity was significantly reduced with an ACE-I.50 It is
important to note that patients similar to those
enrolled in the RENAAL study were excluded from
HOPE. More specifically, increased levels of urinary
protein and serum creatinine that characterise the
RENAAL patients were not permitted in the HOPE
study.50 Additionally,only 47% of HOPE patients were
hypertensive at baseline, unlike RENAAL, where
approximately 94% were hypertensive. On the con-
trary, cardiovascular risk factors, such as established
coronary artery disease and prior MI, were notably
higher among patients in the HOPE study (80% and
53%, respectively) compared with those in RENAAL
(19% and 11%, respectively).50 Therefore, when
assessing the relevance of such studies as HOPE to
RENAAL, it is essential to consider that the risks and
benefits of blockade of the RAAS have never been
established in patients with Type 2 diabetes and
advanced nephropathy. The RENAAL study will
address such risks as hyperkalaemia and cardiovas-
cular disease coupled with impaired renal function
in patients taking a drug which inhibits the RAAS.
There are other long-term trials, that are current-
ly underway, which will address the effects of block-
ade of the RAAS in high-risk patients with hyperten-
sion.Specifically,it will be interesting to compare the
prospective results of the ALLHAT 51 study with those
of RENAAL. The results of ALLHAT (diabetics:
n=15,281 (36%))52 will be more relevant to the
RENAAL population, in that all patients enrolled in
ALLHAT are hypertensive. In this study, all patients
were treated with an antihypertensive drug, either
CCB, ACE-I, alpha-blocker or diuretic. The most
recent news regarding ALLHAT is the termination
of the alpha-blocker arm due to a higher incidence
of cardiovascular events, especially congestive
heart failure.53 To date, there is no indication that
the ACE-I arm is demonstrating superiority over the
other treatment groups.
Considering the fact that approximately 90% of
the diabetic population consists of patients with
Type 2 diabetes, the results of the RENAAL study will
have important clinical implications for physicians
managing patients with diabetes mellitus. RENAAL
is expected to underscore the clinical benefits of
effective blockade of Ang II in progression of Type 2
diabetic nephropathy,as well as to help to determine
whether simply lowering blood pressure in Type 2
diabetes with standard antihypertensives is adequate
to achieve maximal renal protective benefits. If
the results of the RENAAL study prove that block-
ade of the RAAS has a beneficial effect on delaying
the progression of renal disease and mortality, it is
likely that losartan will complement existing ther-
apeutic options to improve survival and quality of
life as well as reduce the healthcare burden of
ESRD in patients with Type 2 diabetes and
nephropathy.
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